Alice Zhang, Chief Executive Officer and Co-Founder, Among the Most Exceptional Entrepreneurs at 2022 Builders and Innovators Summit

Verge Genomics, a tech-enabled drug discovery company pioneering the use of artificial intelligence (AI) and human data to develop new drugs, announced today that Goldman Sachs (NYSE: GS) is recognizing Verge’s Chief Executive Officer and co-founder, Alice Zhang, as one of the Most Exceptional Entrepreneurs of 2022 at its Builders and Innovators Summit in Healdsburg, California.

Goldman Sachs selected Zhang from leaders and entrepreneurs across multiple industries. Verge deeply integrates new advances in hardware, software, and molecular technologies across the entire drug development process to find better drugs, faster. The company pursues a simple but radical premise: to successfully develop medicines for humans, we need to start with humans. Alice has been recognized for her work as a Forbes 30 Under 30 Featured Honoree, MIT Technology Review’s Innovator Under 35, and the San Francisco Business Times’ 40 Under 40. She currently sits on the board of directors at the California Life Sciences Association. Prior to Verge, she spent five years in the UCLA-Caltech MD/PhD program and received her BA degree from Princeton University in Molecular Biology. Alice also is an angel investor and advisor for over 20 tech-enabled bio startups.

“I’m grateful to Goldman Sachs to be recognized alongside such outstanding entrepreneurs that are working to make a positive impact on society in so many diverse areas,” said Zhang. “It is exciting to see the new opportunities for growth and innovation created by these individuals who are shaping the futures of their industries.”

“We’re delighted to recognize Alice Zhang as one of the most exceptional entrepreneurs of 2022,” said David M. Solomon, Chairman and CEO of Goldman Sachs. “They have made extraordinary contributions to a wide range of fields, and all of us are looking forward to meeting with these innovative thinkers.”

In addition to honoring the most exceptional entrepreneurs, the Summit consists of general sessions and clinics led by seasoned entrepreneurs, academics and business leaders as well as resident scholars.

About Verge Genomics

Verge uses AI and human data to develop better drugs faster for the most challenging diseases of our generation. Verge has built CONVERGE™, an end-to-end drug discovery and development platform, that integrates multiple technological innovations from discovery to translation to streamline drug development. Its pioneering use of the industry’s most advanced all-in-human AI-powered drug discovery platform identifies new medicines more efficiently and with an improved probability of success.

Verge is one of the first AI-enabled drug discovery companies to internally develop a clinical candidate from a novel target discovered from its platform. Verge has further demonstrated the power of CONVERGE™ by delivering a broad pipeline spanning diverse therapeutic areas, with its first program, an investigational PIKfyve inhibitor for the treatment of ALS, expected to enter the clinic in 2022. The company is led by experienced drug developers and computational biologists with a shared belief that technology has created a new opportunity to deliver life-changing medicines more efficiently.

For additional information, please visit www.vergegenomics.com. Follow us on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221012005116/en/